XML 83 R35.htm IDEA: XBRL DOCUMENT v3.20.1

Segments (Tables)

3 Months Ended

Mar. 31, 2020

Summary of Segment Profit

a. Segment information:

		Three months ended March 31,
		2020
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	2,082			$	1,402			$	565
Gross profit			1,062				823				305
R&D expenses			146				55				15
S&M expenses			251				202				106
G&A expenses			118				66				34
Other income			(2	)			(1	)			(6	)
Segment profit		$	550			$	502			$	156
		Three months ended March 31,
		2019
		North America				Europe				International Markets*
		(U.S. $ in millions)
Revenues		$	2,047			$	1,264			$	521
Gross profit			1,039				730				269
R&D expenses			165				66				22
S&M expenses			268				215				115
G&A expenses			112				48				36
Other (income) expense			(4	)			(1	)			—
Segment profit		$	498			$	403			$	97

* The data presented for prior periods have been revised to reflect a revision in the presentation of net revenues and cost of sales in the consolidated financial statements. See note 1c for additional information.

Schedule Of Consolidated Income Before Income Tax

		Three months ended March 31,
		2020				2019
		(U.S. $ in millions)
North America profit		$	550			$	498
Europe profit			502				403
International Markets profit			156				97
Total reportable segments profit			1,208				998
Profit of other activities			36				21
Total segments profit			1,244				1,019
Amounts not allocated to segments:
Amortization			258				283
Other assets impairments, restructuring and other items			121				1
Intangible asset impairments			649				469
Legal settlements and loss contingencies			(25	)			57
Other unallocated amounts			49				75
Consolidated operating income (loss)			191				134
Financial expenses, net			224				218
Consolidated income (loss) before income taxes		$	(33	)		$	(84	)

Schedule of Net Sales by Product Line

The following tables present revenues by major products and activities for the three months ended March 31, 2020 and 2019:

North America		Three months ended March 31,
		2020				2019
		(U.S. $ in millions)
Generic products		$	952			$	966
AJOVY			29				20
AUSTEDO			122				74
BENDEKA/TREANDA			105				122
COPAXONE			198				208
ProAir*			59				59
QVAR			45				64
Anda			426				379
Other			146				155
Total		$	2,082			$	2,047

* Does not include revenues from the ProAir authorized generic, which are included under generic products.

Europe		Three months ended March 31,
		2020				2019
		(U.S. $ in millions)
Generic products		$	1,032			$	919
COPAXONE			109				114
Respiratory products			106				91
AJOVY			4				—
Other			151				140
Total		$	1,402			$	1,264

International markets*		Three months ended March 31,
		2020				2019
		(U.S. $ in millions)
Generic products		$	449			$	441
COPAXONE			12				13
Other			104				67
Total		$	565			$	521

* The data presented for prior periods have been revised to reflect a revision in the presentation of net revenues and cost of sales in the consolidated financial statements. See note 1c for additional information.

X

- Definition

Schedule of consolidated income before income tax.

+ References

No definition available.

+ Details

Name:	teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock
Namespace Prefix:	teva_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration